The PXR rs7643645 Polymorphism Is Associated with the Risk of Higher Prostate-Specific Antigen Levels in Prostate Cancer Patients

Octavio D. Reyes-Hernández1, Libia Vega2, Miguel A. Jiménez-Ríos2, Pedro F. Martínez-Cervera3, Juan A. Lugo-García1, Leticia Hernández-Cadena4, Patricia Ostrosky-Wegman5, Lorena Orozco6, Guillermo Elizondo7*

1Laboratorio de Genética y Diagnóstico Molecular, Hospital Juárez de México, México, D.F., México, 2Departamento de Toxicología, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, México, D.F., México, 3Departamento de Urología, Instituto Nacional de Cancerología, México, D.F., México, 4Departamento de Salud Ambiental, Instituto Nacional de Salud Pública, México, D.F., México, 5Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México, D.F., México, 6Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, México, D.F., México, 7Departamento de Biología Celular, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, México, D.F., México

Abstract

Levels of enzymes that determine testosterone catabolism such as CYP3A4 have been associated with prostate cancer (PCA) risk. Although some studies have related CYP3A4*18 allele, a gene polymorphism that modifies CYP3A4 expression level, with PCA risk, others have failed, suggesting that additional genetic variants may be involved. Expression of CYP3A4 is largely due to the activation of Pregnane X Receptor (PXR). Particularly, rs2472677 and rs7643645 PXR polymorphisms modify CYP3A4 expression levels. To evaluate whether PXR-HNF3β/T (rs2472677), PXR-HNF4/G (rs7643645), and CYP3A4*1B (rs2740574) polymorphisms are associated with PCA a case control-study was performed. The multiple testing analysis showed that the PXR-HNF4/G polymorphism was associated with higher levels of prostate-specific antigen (PSA) in patients with PCA (OR = 3.99, p = 0.03). This association was stronger in patients diagnosed at the age of 65 years or older (OR = 10.8, p = 0.006). Although the CYP3A4*1B/*1B genotype was overrepresented in PCA patients, no differences were observed in the frequency of this and PXR-HNF3β/T alleles between controls and cases. Moreover, no significant association was found between these polymorphisms and PSA, Gleason grade, or tumor lymph node metastasis.

Introduction

Prostate cancer (PCA) is the second most common cancer worldwide in males and one of the most common causes of death in men (IARC, 2008). The etiology of the disease involves several factors, including ethnicity, older age, family history, and genetic and environmental factors [1,2]. It has been established that steroid hormone levels, in particular androgens, affect the risk of developing PCs [3,4]. Testosterone and predominantly its metabolite dihydrotestosterone interact with the androgen receptor, which leads to the expression of genes involved in the growth of the prostate and the proliferation of prostate cancer cells [5]. Several cytochromes P450s (CYPs) are involved in the synthesis and catabolism of hormones, such as testosterone [6]. The bioavailability of dihydrotestosterone is decreased by CYP3A4, which mediates the 2β-, 6β-, and 15β-hydroxylation of testosterone in the liver and prostate [7–9]. Therefore, it has been hypothesized that low levels and/or decreased CYP3A4 activity might result in a lower capacity to inactivate testosterone favoring its conversion to dihydrotestosterone and increasing the risk of developing PCs. In fact, decreased expression of CYP3A4 has been found in prostatic tissues from PCa patients compared to 93% for benign epithelium, and only 75% of prostate tumors expressed CYP3A4 [10].

Interindividual variation in CYP3A4 levels of up to 60-fold have been reported [11,12], and it has been suggested that most of the variability can be explained by genetic factors [13]. The CYP3A4 gene is highly polymorphic, and to date, 43 different CYP3A4 polymorphisms have been reported (http://www.cypalleles.ki.se/), of which CYP3A4*1B is one of the most common. CYP3A4*1B is a single nucleotide polymorphism (SNP) (rs2740574) that introduces an A to G substitution at position −290, which is located in the nifenipine specific response element of the promoter of the CYP3A4 gene. While some studies have reported associations between the CYP3A4*1B allele and higher clinical grade of PCs [14,15], others have failed to observe an association between the presence of the CYP3A4*1B polymorphism and prostate cancer susceptibility [16,17]. Controversial data regarding the association of CYP3A4*1B and CYP3A4 activity have also been reported [18,19], suggesting that other genetic variants may be involved, such as transcription factors that mediate CYP3A4 expression.
**Table 1.** Characteristics of the study subjects.

| Residence area   | No. of subjects (%) | Case     | Control  | p value* |
|------------------|---------------------|----------|----------|----------|
| South central    | 71 (76.34)          | 123 (68.49) | 0.01*    |
| North central    | 3 (3.23)            | 2 (1.44)  | 0.392*   |
| Southeast        | 7 (7.52)            | 2 (1.44)  | 0.032*   |
| Northeast        | 1 (1.08)            | 0 (0.0)   | 0.401*   |
| East             | 9 (9.68)            | 10 (7.19) | 0.49*    |
| West             | 2 (2.15)            | 2 (1.44)  | 0.999*   |

| Marital status   | No. of subjects (%) | Case     | Control  | p value* |
|------------------|---------------------|----------|----------|----------|
| Married          | 71 (71.71)          | 95 (68.84) | 0.47*    |
| Divorced         | 4 (4.04)            | 8 (5.80)  | 0.203*   |
| Cohabitation     | 8 (8.09)            | 8 (5.80)  | 0.46*    |
| Single           | 4 (4.04)            | 15 (10.87)| 0.087*   |
| Widow            | 12 (12.12)          | 12 (8.70) | 0.35*    |

| Age (Median ± S.D.)* | 67.56±8.3       | 68.61±7.9   | 0.25*    |

| Clinical characteristics | No. of subjects (%) | Case     | Control  | p value* |
|-------------------------|---------------------|----------|----------|----------|
| PSA (Median ± S.D.)*    | 167.36±589.64      | 1.73±1.03 | 0.001*   |

| DRE                     | No. of subjects (%) | Case     | Control  | p value* |
|-------------------------|---------------------|----------|----------|----------|
| Grade I                 | 8 (19.51)           | 38 (29.93)| 0.17*    |
| Grade II                | 21 (51.22)          | 79 (62.20)| 0.23*    |
| Grade III               | 12 (29.27)          | 10 (7.87) | 0.0004*  |

Pregnane X receptor (PXR, NR1I2) is a member of the steroid nuclear receptor family of ligand activated transcription factors. Activated-PXR forms a heterodimer with 9-cis-retinoic acid X receptor (RXR) and binds to a nuclear receptor response element in the 5′-flanking region of its target genes. Induction of CYP3A4 is largely due to the activation of PXR [20]. Therefore, genetic variants of PXR that alter PXR protein levels or its transactivation potential may have an important impact on CYP3A4 expression. Several PXR polymorphisms have been described to date, but only a few have an effect on CYP3A4 expression. Among them, we found rs2472677 and rs7643645. The rs7643645 SNP is located in the HNF4 binding site of the promoter of the PXR gene and has been associated with decreased PXR and CYP3A4 mRNA levels as well as CYP3A4 activity. The rs2472677 variant is located in the HNF3β binding site of the same promoter and results in increased PXR mRNA levels as well as basal CYP3A4 activity [21]. For practical purposes, in the present study the rs7643645 variant will be called PXR-HNF4/G or PXR-HNF4/WT and the rs2472677 variant will be called PXR-HNF3β/T or PXR-HNF3β/WT.

So far, there have been no reports in the literature exploring the possible association between PXR polymorphisms and PCa. Therefore, we performed a case-control study to investigate whether CYP3A4*1B, PXR-HNF4/G, and PXR-HNF3β/T allele variants are associated with a risk of developing PCa in Mexican men.

**Materials and Methods**

**Study population**

The present study used a hospital-based case-control design. The case group was recruited from the National Institute of Cancer and included 99 patients with a histologically confirmed diagnosis of PCa. Clinical characteristics, such as Gleason grade, prostate-specific antigen (PSA) levels at the time of diagnosis, digital rectal examination (DRE; according to the American Urological Association recommendations), tumor lymph node metastasis (TNM) [22], and age at the time of diagnosis were obtained from medical records. Categories of clinical characteristics were defined as follows: PSA two groups, (cut point, 10 ng/mL); Gleason grade two groups (cut point, 7); and TNM two groups (TNM#2 and TNM$3) [15]. The control group consisted of 144 patients with no history of any cancer, including prostate cancer, with a PSA, 4.0 ng/mL, normal DRE, and was recruited from the Juárez Hospital. All subjects were unrelated men (self-reporting) between 60 and 76 years of age. The National Institute of Cancer and the Juárez Hospital Ethics Committees approved the present study and written informed consent was obtained from all subjects. The complete clinical and genetic per-patient data can be found in the supporting information (Table S1 and S2).

**DNA extraction**

Genomic DNA was isolated from 5 ml of whole blood using a sodium perchlorate/chloroform extraction method. Briefly, DNA was prepared by combining each blood sample with 35 ml of lysis

---

**Table 1.** Characteristics of the study subjects.

| Residence area    | No. of subjects (%) | Case     | Control  | p value* |
|-------------------|---------------------|----------|----------|----------|
| South central     | 71 (76.34)          | 123 (68.49) | 0.01*    |
| North central     | 3 (3.23)            | 2 (1.44)  | 0.392*   |
| Southeast         | 7 (7.52)            | 2 (1.44)  | 0.032*   |
| Northeast         | 1 (1.08)            | 0 (0.0)   | 0.401*   |
| East              | 9 (9.68)            | 10 (7.19) | 0.49*    |
| West              | 2 (2.15)            | 2 (1.44)  | 0.999*   |

| Marital status    | No. of subjects (%) | Case     | Control  | p value* |
|-------------------|---------------------|----------|----------|----------|
| Married           | 71 (71.71)          | 95 (68.84) | 0.47*    |
| Divorced          | 4 (4.04)            | 8 (5.80)  | 0.203*   |
| Cohabitation      | 8 (8.09)            | 8 (5.80)  | 0.46*    |
| Single            | 4 (4.04)            | 15 (10.87)| 0.087*   |
| Widow             | 12 (12.12)          | 12 (8.70) | 0.35*    |

| Age (Median ± S.D.)* | 67.56±8.3       | 68.61±7.9   | 0.25*    |

| Clinical characteristics | No. of subjects (%) | Case     | Control  | p value* |
|-------------------------|---------------------|----------|----------|----------|
| PSA (Median ± S.D.)*    | 167.36±589.64      | 1.73±1.03 | 0.001*   |

| DRE                     | No. of subjects (%) | Case     | Control  | p value* |
|-------------------------|---------------------|----------|----------|----------|
| Grade I                 | 8 (19.51)           | 38 (29.93)| 0.17*    |
| Grade II                | 21 (51.22)          | 79 (62.20)| 0.23*    |
| Grade III               | 12 (29.27)          | 10 (7.87) | 0.0004*  |

PSA, prostate specific antigen. DRE, digital rectal examination. *x² test.

*P<0.05.

*p values were obtained using t² test or one way ANOVA test as applied.

DOI:10.1371/journal.pone.0099974.t001
buffer [320 mM sucrose, 5 mM MgCl₂, 1% (v/v) Triton X-100, 10 mM Tris-HCl, pH 8]. The nuclear pellet was collected by centrifugation at 2000 × g for 10 min and then resuspended in 2 mL of solution B [150 mM NaCl, 60 mM EDTA, 1% (v/v) sodium dodecyl sulfate, 400 mM Tris-HCl, pH 8]. The suspension was mixed with 0.5 mL of 5 M sodium perchlorate and then incubated at 65 °C for 30 min. Following the incubation, 2 mL of chloroform was added, and the mixture was centrifuged at 14000 × g for 10 min. The aqueous DNA-containing upper phase was precipitated by addition of 2 volumes of 100% ethanol and washed with 70% ethanol. The DNA was then resuspended in 200 μL of 10 mM Tris-HCl, 1 mM EDTA, pH 7.4, and quantified by measuring absorbance at a wavelength of 260 nm.

Genotyping

Genotyping of CYP3A4*1B, PXR-HNF3β, and PXR-HNF4 was conducted by real-time PCR using a StepOne Real-Time PCR System with TaqMan Universal PCR Master Mix (Applied Biosystems, USA). PCR was conducted using 5 μl of TaqMan Universal PCR Master Mix, 0.25 μl of primer-probe mix (containing 36 μM of each primer and 8 μM of dye-labeled probe), and 20 μg of DNA template. The final reaction volume was brought to 10 μl with H₂O. Forty PCR cycles of the following parameters were used: initial denaturation at 95 °C for 10 min, 15 s at 92 °C, and then 60 °C for 1 min. After each amplification an allelic discrimination was made to determine the genotype of each subject. The primers and probes sequences used for CYP3A4 were as follows: 5'-TGGAAATGACAGGGCAGCATAGAGA-3' (forward), 5'-AGTGGAGCCATGGGCATAAAATCTC-3' (reverse), *1A probe (VIC): AAGGGCAAGAGAG, and *1B probe (FAM): TGGCCCGTGGTCC.

For PXR-HNF3β, 5'-GCCACAAACATTTTCAATGGTAGGATTA-3' (forward), 5'-CATCTGGAAGAGCTATTCTATCTCGTCTC-3' (reverse), PXR-HNF3β/WT probe (VIC): CGATATTCTTGTGGATTA, and PXR-HNF3β/T probe (FAM): CGATATTCTTGTGGATTA. For PXR-HNF4, 5'-GCCAGATCACACATGGGAGA-3' (forward), PXR-HNF4/WT probe (VIC): AAAATGCGCTGTGGTCC, and PXR-HNF4/G probe (FAM): TGGCCCGTGGTCC.

Statistical analysis

Statistical analysis was conducted using the STATA statistical package (version 10.1, STATA Corp., College Station, TX). T-test, X² test or Fisher’s exact test were used to evaluate whether the distribution of genotype frequencies of CYP3A4*1B, PXR-HNF4, and PXR-HNF3β varied among cases and controls. For the comparison of clinical characteristics in the case group, ORs were calculated as an estimate of relative risk and 95% confidence intervals (CIs) were calculated using a bivariate logistic model. A value of p<0.03 was considered statistically significant after multiple testing adjustment by using the Bonferroni correction. The X² test was also used to assess deviations of allelic frequencies from Hardy-Weinberg equilibrium. The interaction between alleles was analyzed using the software Plink V 1.07. The number (n) of the case population for each association with clinical characteristics is indicated in the tables.

The sensitivity and specificity from significant models were estimated [23]. A cutoff of 50% for the classification of the event and the Receiver Operating Characteristic (ROC) curve were used. All calculations were performed using STATA as post logistic model estimation.

Results

Clinical characteristics of the studied subjects were obtained from medical records and are presented in Table 1. No differences were observed in marital status or age between the two groups. As expected, prostate cancer patients presented significantly higher levels of PSA than in the control group (167 vs. 1.73 ng/mL, respectively) as well as a higher score for DRE grade III.

Analysis between case and control groups

The genotype frequencies of CYP3A4 and PAR between prostate cancer patients and controls are shown in Table 2. Alleles for PAR were in Hardy-Weinberg equilibrium (HWE), but CYP3A4*1B was only in HWE in the control group (data not shown). The CYP3A4*1B/*1B genotype was only present in prostate cancer patients. No differences were observed for CYP3A4*1A/*1B or CYP3A4*1A/*1A genotypes between both groups. Moreover, when PAR polymorphisms were compared between case and

| Genotype                  | Case (n, %) | Control (n, %) | p value |
|---------------------------|------------|---------------|---------|
| CYP3A4                    |            |               |         |
| *1A/*1A                   | 83 (83.83) | 116 (80.56)   | 0.51 *  |
| *1A/*1B                   | 12 (12.12) | 28 (19.44)    | 0.13 *  |
| *1B/*1B                   | 4 (4.04)   | 0 (0)         | 0.01 *  |
| PXR-HNF3β                 |            |               |         |
| WT/WT                     | 40 (40.40) | 50 (34.72)    | 0.36 *  |
| WT/T                      | 43 (43.43) | 72 (50.00)    | 0.31 *  |
| T/T                       | 16 (16.16) | 22 (15.28)    | 0.85 *  |
| PXR-HNF4                  |            |               |         |
| WT/WT                     | 21 (21.21) | 26 (18.06)    | 0.54 *  |
| WT/G                      | 45 (45.45) | 75 (52.08)    | 0.30 *  |
| G/G                       | 33 (33.33) | 43 (29.86)    | 0.56 *  |

* x² test.
Fisher’s exact test.
n, No. of subjects.

doi:10.1371/journal.pone.0099974.t002

Association of PXR Polymorphism and PSA Levels
control groups, no differences in genotype frequencies for either PXR-HNF3β or PXR-HNF4G alleles were observed.

We then determined the distribution of the combined CYP3A4 and PXR allelic variants. Individuals with the combined genotypes CYP3A4*1B/*1B and PXR-HNF4G/G, or CYP3A4*1B/*1B and PXR-HNF3β/T/T were included in Table 3.

### Table 3. Distribution of combined CYP3A4 and PXR allelic variants.

| Genotype       | CYP3A4 *1A/*1A (n, %) | CYP3A4 *1A/*1B (n, %) | CYP3A4 *1B/*1B (n, %) | PXR-HNF3β | PXR-HNF4G/G |
|----------------|-----------------------|-----------------------|-----------------------|------------|-------------|
|                | Case                  | Control               | p value               | Case       | Control     | p value |
| PXR-HNF3β      |                       |                       |                       |            |             |         |
| WT/WT          | 34 (34.34)            | 40 (27.78)            | 0.27†                 | 2 (0.02)   | 10 (6.94)   | 0.08†   | 3 (0.03) | 0 (0.0) | 0.03†   |
| WT/T           | 35 (35.35)            | 59 (40.97)            | 0.37†                 | 8 (0.08)   | 13 (9.02)   | 0.79†   | 1 (0.01) | 0 (0.0) | 0.22†   |
| T/T            | 14 (14.14)            | 17 (11.80)            | 0.59†                 | 2 (0.02)   | 5 (3.47)    | 0.50†   | 0 (0.0)  | 0 (0.0) | NA      |
| PXR-HNF4G/G    |                       |                       |                       |            |             |         |
| WT/WT          | 16 (16.16)            | 21 (14.58)            | 0.73†                 | 5 (0.05)   | 5 (3.47)    | 0.54†   | 0 (0.0)  | 0 (0.0) | NA      |
| WT/G           | 40 (40.40)            | 59 (40.98)            | 0.92†                 | 5 (0.05)   | 16 (11.11)  | 0.09†   | 0 (0.0)  | 0 (0.0) | NA      |
| G/G            | 27 (27.27)            | 36 (25.00)            | 0.69†                 | 2 (0.02)   | 7 (4.86)    | 0.24†   | 4 (0.04) | 0 (0.0) | 0.01†   |

*χ² test. †Fisher's exact test. NA, not applicable.

Table 3 provides the distribution of combined CYP3A4 and PXR allelic variants. The results indicate no significant differences between case and control groups in the frequencies of CYP3A4 and PXR genotypes.

**Figure 1.** Association between CYP3A4 (A), PXR-HNF3β (B), and PXR-HNF4G (C) genotypes and clinical characteristics among case and control groups. The ORs were calculated as an estimate of relative risk, and 95% confidence intervals (CI) were calculated using a bivariate logistic model. PSA, prostate-specific antigen; TNM, tumor, lymph node, and metastasis. *p = 0.03.

**Table 3.** Distribution of combined CYP3A4 and PXR allelic variants.

- **CYP3A4**
  - *1A/*1A (n, %): Case 34 (34.34), Control 40 (27.78), p value 0.27†
  - *1A/*1B (n, %): Case 2 (0.02), Control 10 (6.94), p value 0.08†
  - *1B/*1B (n, %): Case 3 (0.03), Control 0 (0.0), p value 0.03†

- **PXR-HNF3β**
  - WT/WT: Case 34 (34.34), Control 40 (27.78), p value 0.27†
  - WT/T: Case 35 (35.35), Control 59 (40.97), p value 0.37†
  - T/T: Case 14 (14.14), Control 17 (11.80), p value 0.59†

- **PXR-HNF4G/G**
  - WT/WT: Case 16 (16.16), Control 21 (14.58), p value 0.73†
  - WT/G: Case 40 (40.40), Control 59 (40.98), p value 0.92†
  - G/G: Case 27 (27.27), Control 36 (25.00), p value 0.69†
PXR-HNF3β WT/WT, were only present in the case group. For the other combinations, no differences were observed between control and case groups (Table 3).

Analysis among cases

Stratification of the CYP3A4 and PXR genotypes and PSA, Gleason grade, and TNM score among prostate cancer patients are shown in Figure 1 and Table S3. There were no differences in the CYP3A4 genotype by comparison of PSA or Gleason grade. Twenty-five percent of the prostate cancer patients with a TNM $3 were heterozygous for the CYP3A4 variant and had an OR of 3.16 compared to the *1A/*1A genotype, but this difference was not statistically significant ($p = 0.10$) (Table S3). For the PXR-HNF4 genotype, an association of PXR-HNF4/G variant with higher PSA levels was observed in case group (Figures 1 and 2). Individuals with PSA > 10 ng/ml were WT/G (49.2%) and G/G (34.92%) with ORs of 2.46 ($p = 0.10$) and 3.99 ($p = 0.03$), respectively. On the other hand, sixty-two percent of the cases with a TNM $\geq 3$ were heterozygous for the PXR-HNF4 allele with an OR of 2.96, but this result was not statistically significant. No associations were observed for PXR-HNF4 genotypes with the Gleason grade. The PSA, Gleason grade, and TNM score values were not associated with the PXR-HNF3β genotype among PCa patients. In order to determine the power of the present study for PXR-HNF4 polymorphism a power analysis was performed, and a 1-$\beta$ value of 84 was obtained (Figure 3).

A stronger association between the CYP3A4 genotype and Gleason and TNM grades in patients diagnosed at the age of 65 years or older has been reported previously [15]. Therefore, we investigated the association of CYP3A4 and PXR-HNF4 genotypes with clinical characteristics among individuals diagnosed at the age of 65 years or older. In order to compare the results with those previously reported, a dominant model was used (i.e. WT versus heterozygous and homozygous for the variant).

No association between CYP3A4 genotypes and PSA or Gleason grade were observed. However, men with *1B allele showed an increased risk of having a higher TNM score (OR = 2.2), but the statistical analysis indicated that this association was not significant (Table 4). Table 5 shows ORs comparing PXR-HNF4/WT to PXR-HNF4 WT/G and PXR-HNF4 -G/G in combination (dominant model). The data indicate that men with the G variant showed an increased risk of having higher PSA levels (OR = 10.8; $p = 0.006$). Sensitivity and specificity analysis indicate that 84% of individuals over 65 years old with WT/G or G/G genotype will have a high risk to present higher levels of PSA.

PSA, prostatic-specific antigen. TNM, tumor lymph nodes metastasis.

* Comparing those with WT versus those with G/G and WT/G genotypes (dominant model).

Logistic model.

n, No. of subjects.

No associations with Gleason grade and TNM score were identified. Taken together, these results clearly indicate that PXR-HNF4/G polymorphisms increase the risk of having higher PSA levels among cancer prostate patients.

Figure 2. PXR-HNF4/G variant is associated with higher PSA levels. Individuals from the case group were genotyped for PXR-HNF4/G variant and divided in groups according to their genotype: 20 individuals corresponded to homozygous PXR-HNF4-WT/WT, 45 corresponded to heterozygous PXR-HNF4-WT/G, and 28 corresponded to PXR-HNF4-G/G. The data were analyzed by using the Mann Whitney U test. Horizontal line indicates the median. WT/WT vs WT/G, $p = 0.05$; WT/WT vs G/G, $p = 0.02$.

doi:10.1371/journal.pone.0099974.g002

Figure 3. A power analysis for PXR-HNF4 polymorphism was calculated considering an effect size (OR) equal to 3.9, a balanced design ($p = 0.5$) with equal sample frequencies for $X = 0$ and $X = 1$, in a two-sided test with $\alpha = 0.05$. It was also considered the pseudo R2, logistic model ($R^2 = 0.0432$). For a sample size of 93 individuals the power calculated was 0.84.

doi:10.1371/journal.pone.0099974.g003
The etiology of prostate cancer still remains unclear and involves several factors, including genetic determinants. Therefore, the identification of genetic risk factors for prostate cancer susceptibility is important. Many studies have focused on \textit{CYP3A4} gene polymorphisms because this enzyme participates in testosterone metabolism. In the present case-control study, we investigated whether \textit{CYP3A4*1B} variant was associated with several clinic characteristics of prostate cancer. The \textit{CYP3A4*1B} variant was not in HWE in the case group most likely due to the excess of homozygous \textit{CYP3A4*1B} genotype presented in this group. Deviation from HWE should not be unexpected, particularly when an allele is associated with a disease, which is the case in this study. In fact, similar studies show data that do not meet the Hardy-Weinberg population laws [14, 15, 24]. Although the \textit{CYP3A4*1B/*1B} genotype is overrepresented in prostate cancer patients, no differences were observed in the frequency of this allele between controls and cases (Table S4). Moreover, no association of this polymorphism with PSA, Gleason grade, or TNM was observed. On the other hand, it has been reported that the incidence rate of PCa is higher in patients with benign prostatic hyperplasia having the \textit{CYP3A4*1B} allele compared to those having the \textit{CYP3A4*1A} allele [25]. Considering the above, it would be interesting to assess whether this association is also present in the Mexican population. Another important consideration is the potential clinical impact of the \textit{CYP3A4*1B} variant on the individual response to hormonal therapy. A previous study reported a stronger association between the \textit{CYP3A4*1B} genotype and Gleason grade and TNM score in patients diagnosed at the age of 65 years or older [14, 15]. In the present patients population, the dominant model analysis showed that individuals diagnosed at the age of 65 years or older and with the \textit{CYP3A4*1B} allele had a higher risk of a TNM $\geq 3$ (OR = 2.2). However, this increase was not statistically significant. Moreover, the present study did not find an association between \textit{CYP3A4*1B} polymorphisms and clinic characteristics of prostate cancer. Other studies have also failed to show an association between prostate cancer and this allelic variant [17]. The functional significance of the \textit{CYP3A4*1B} polymorphism has been studied using \textit{in vitro} and \textit{in vivo} approaches. Transactivation studies indicate that the -290A/G variant results in an increase in reporter gene activity, suggesting that the \textit{CYP3A4*1B} polymorphism is unlikely to decrease the capacity to inactivate testosterone and therefore

| Clinic characteristics | \textit{CYP3A4} genotype, n (%) | OR (95% CI) * | *p value |
|------------------------|---------------------------------|---------------|---------|
|                        | *1A/*1A | *1A/*1B | *1B/*1B |
| PSA at diagnosis (n = 41) |        |         |         |
| $\leq$10               | 7 (77.78) | 1 (11.11) | 1 (11.11) | 1.0 |
| $>10$                  | 25 (78.13) | 3 (9.27) | 4 (12.50) | 1.0 (0.17-6.05) | 0.98 |
| Gleason grade (n = 36) |        |         |         |
| $\leq$7                | 11 (73.33) | 1 (6.67) | 3 (20.00) | 1.0 |
| $>7$                   | 17 (80.96) | 2 (9.52) | 2 (9.52) | 1.5 (0.31-7.50) | 0.58 |
| TNM grade (n = 33)     |        |         |         |
| $\leq$2                | 22 (81.48) | 1 (3.70) | 4 (14.82) | 1.0 |
| $\geq$3                | 4 (66.68) | 1 (16.66) | 1 (16.66) | 2.2 (0.31-15.54) | 0.42 |

PSA, prostatic-specific antigen. TNM, tumor lymph nodes metastasis. *Comparing those with *1A/*1A versus those with *1B/*1B and *1A/*1B genotypes (dominant model). **Logistic model.

Table 4. Association of \textit{CYP3A4} genotype and clinical characteristics in patients diagnosed at the age of $\geq$65.

| Clinic characteristics | \textit{PXR-HNF4} genotype, n (%) | OR (95% CI) * | *p value |
|------------------------|-----------------------------------|---------------|---------|
|                        | WT/WT | WT/G | G/G |
| PSA at diagnosis (n = 41) |        |         |         |
| $\leq$10               | 2 (66.66) | 2 (22.22) | 1 (11.11) | 1.0 |
| $>10$                  | 5 (15.63) | 15 (46.87) | 12 (37.50) | 10.8 (2.00-58.10) | 0.006 |
| Gleason grade (n = 36) |        |         |         |
| $\leq$7                | 4 (26.67) | 5 (33.33) | 6 (40.00) | 1.0 |
| $>7$                   | 6 (28.57) | 9 (42.86) | 6 (28.57) | 0.9 (0.20-4.01) | 0.90 |
| TNM score (n = 33)     |        |         |         |
| $\leq$2                | 7 (25.92) | 10 (37.04) | 10 (37.04) | 1.0 |
| $\geq$3                | 2 (33.33) | 3 (50.00) | 1 (16.67) | 0.7 (0.10-4.69) | 0.71 |

Table 5. Association of \textit{PXR-HNF4} genotype and clinical characteristics in patients diagnosed at the age of $\geq$65.
increase the risk for PCa development [26] [27]. More controversial results regarding in vivo studies have been reported. Wandel and collaborators [19] showed a modest difference in CYP3A4 activity between African Americans and European Americans associated with the CYP3A4*1B frequency. However, Lamba and collaborators [29] did not find any association between this polymorphism and the CYP3A4 phenotype. Ball [29] reported similar results. The lack of a correlation could be explained by other genetic polymorphisms involved in hormone metabolism, such as those presented at the CYP3A4 gene. Moreover, sequence variation of transcription factors that modulate the expression of CYP3A4 and other hormone metabolizing enzymes should be considered as well. In particular, PXR may play an important role, since several transporters and metabolizing enzymes, including CYP3A4, are under its transcriptional regulation. In the present study, neither PXR-HNF4/G nor PXR-HNF3β/T alleles were over represented in case group. However, a clear association between the PXR-HNF4/G allele and PSA levels was observed. We found that heterozygous and homozygous prostate cancer patients had a higher risk of presenting higher levels of PSA (OR = 2.46 and OR = 3.99, respectively). When the analysis was applied to patients diagnosed at the age of 65 years or older, the dominant model analysis showed that individuals with this allele presented an even higher risk of having high PSA levels (OR = 10.3).

The PXR-HNF4 (69789A>G) polymorphism modifies an HNF4 binding site located in the PXR gene promoter, which results in lower PXR and CYP3A4 mRNA levels together with a decrease in CYP3A4 basal activity [30]. On the other hand, it has been shown that prostate tissue from prostate cancer patients express lower levels of PXR and CYP3A4 proteins compared to benign prostate tissue from control group [31] [10]. This most likely favors the conversion of testosterone to dihydrotestosterone (DHT) increasing the risk of developing PCa as well as prostate cancer markers such as PSA. PSA is a member of the kallikrein gene family. Several data indicate that PSA is under androgenic regulation. Induction of PSA mRNA is driven by mibolerone and DHT and inhibited by antiandrogens, suggesting that this effect is androgen receptor-dependent [32] [33] [34]. Once PSA is secreted it degrades extracellular proteins facilitating the invasion of prostate cancer cells [35]. PSA has been widely used to screen men for PCa leading to a dramatic reduction in PCa death rates. However, its use is controversial due to its limit to distinguish between cancer and benign prostatic hyperplasia, or between indolent and aggressive cancer resulting in overdiagnosis and overtreatment. The present results should be understood by considering the above.

In addition to CYP3A4, PXR regulates the expression of other genes involved in steroid hormone metabolism, such as CYP17 and CYP2A1, which might account for alterations in testosterone bioavailability [36] [37]. The PXR-HNF4/G allele frequency in the control group was 0.37, which is similar to that observed for Caucasians (0.36) [30]. In contrast, this allele frequency in the prostate cancer group was 0.56. However, this difference was not statistically significant. Nevertheless, the presense of the PXR-HNF4/G allele is high in both populations, Caucasian and Mexicans, and therefore it would be interesting to explore possible associations of this polymorphism and drug metabolism as well as other pathologies.

Interestingly, the patients homozygous for the CYP3A4*1B allele were also homozygous for the PXR-HNF4/G allele. Therefore, we investigated whether an epistasis phenomenon was involved and found that the two alleles did not interact.

In summary, the present study is the first to show that the presence of the PXR-HNF4/G allele increases the risk of having higher levels of PSA in patients with prostate cancer. It is also the first study that evaluates, in a Mexican population, the association of CYP3A4 and PXR gene polymorphisms with PCa. In agreement with previous studies, the present data suggest that the CYP3A4*1B polymorphism appears to be a gene with low penetrance and therefore has moderate effects on the risk of developing prostate cancer. Finally, future studies should be performed to assess the PXR variants role in PCa development.

Supporting Information

Table S1 Clinical and genetic per–patient results (Cases).

Table S2 Clinical and genetic per–patient results (Controls).

Table S3 Relation between CYP3A4 and PXR genotypes and clinical characteristics among cases.

Table S4 CYP3A4 and PXR allelic frequencies.

Acknowledgments

We thank Humberto García Ortiz for his technical assistance.

Author Contributions

Conceived and designed the experiments: GE. Performed the experiments: ODRH. Analyzed the data: LV LHC POW LO. Wrote the paper: ODRH.
13. Ozolnir V, Kalow W, Tang BK, Paterson AD, Walker SE, et al. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10: 373–380.
14. Rehbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225–1229.
15. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, et al. (1999) Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8: 901–905.
16. Kittles RA, Chen W, Panghali RK, Aghahotu C, Jackson A, et al. (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 110: 553–560.
17. Taiebi E, Sears V, Watson A, Flores-Obando RE, Jackson MD, et al. (2013) Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent. Prostate 73: 666–676.
18. Kuerhl P, Zhang J, Lin Y, Lamba J, Assen M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383–391.
19. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, et al. (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5 promoter region polymorphism. Clin Pharmacol Ther 68: 82–91.
20. Kliwer SA, Moore JT, Wade L, Staudinger JL, Watson MA, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 75–82.
21. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, et al. (2001) Natural protein variants of progesterone receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29: 1454–1459.
22. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, et al. (1992) The TNM classification of prostate cancer. Prostate Suppl 4: 129–138.
23. Kraft P, Wacholder S, Cornells MC, Hu FB, Hayes RB, et al. (2009) Beyond odds ratios—communicating disease risk based on genetic profiles. Nat Rev Genet 10: 264–269.
24. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, et al. (2002) Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 54: 13–21.
25. Tayeb MT, Clark C, Sharp L, Haitez NE, Rooney PH, et al. (2002) CYP3A4 promoter variants are associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 9: 653–655.
26. Amirian A, Ning B, Deitz AC, Weber BL, Kadiuflbar FF, et al. (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 42: 299–305.
27. Spurdle AB, Goodwin B, Hoolgen E, Hopper JL, Chen X, et al. (2002) The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12: 355–366.
28. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, et al. (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12: 121–132.
29. Ball SE, Scatina J, Kao J, Ferron GM, Frnullo R, et al. (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 66: 283–294.
30. Lamba J, Lamba V, Strom S, Venkataraman R, Schuetz E (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36: 169–181.
31. Fujimura T, Takahashi S, Uruno T, Tanaka T, Zhang W, et al. (2012) Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer. Cancer Sci 103: 176–180.
32. Johnson JL, Ellis EA, Noack D, Seehra MC, Catz SD (2005) The Rhab 27a-binding protein, JFC1, regulates androgen-dependent secretion of prostate-specific antigen and prostatic-specific acid phosphatase. Biochem J 391: 699–710.
33. Young GY, Montgomery JT, Andrews PE, Qui SD, Bilhartz DL, et al. (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51: 3748–3752.
34. Lin MF, Garcia-Arenas R, Chao YC, Lai MM, Patel PC, et al. (1993) Regulation of prostatic acid phosphatase expression and secretion by androgens in LNCaP human prostate carcinoma cells. Arch Biochem Biophys 300: 304–390.
35. Wehler MM, Waghray A, Bello D (1993) Prostate-specific antigen, a serum protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1: 1089–1094.
36. Gray MA, Squires EJ (2013) Effects of nuclear receptor transactivation on boar taint metabolism and gene expression in porcine hepatocytes. J Steroid Biochem Mol Biol 133: 110–119.
37. Konno Y, Kodama S, Moore R, Kamiya N, Negishi M (2009) Nuclear xenobiotic receptor pregnane X receptor locks coressorpressing silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP3A4 promoter to attenuate vitamin D3 activation. Mol Pharmacol 75: 265–271.